- VYNE Therapeutics Inc (NASDAQ:VYNE) announced new preclinical data showing the effect of its novel pan-BET inhibitor, VYN201, in a preclinical model of idiopathic pulmonary fibrosis (IPF).
- VYN201 at 0.5 mg/ml and 1 mg/ml demonstrated statistically significant reductions in Ashcroft scores (a measurement of lung fibrosis) and levels of the tissue fibrosis biomarker compared to the placebo control group.
- Also Read: VYNE Therapeutics Touts Encouraging Pharmacokinetic, Hematology Data From Potential Candidate For Skin Disorder.
- Mean control-adjusted lung fibrosis scores for VYN201 1 mg/ml were 65.8% lower than the placebo control group.
- VYN201 demonstrated a dose-dependent improvement in blood oxygen saturation.
- The mean blood oxygen saturation for the VYN201 1 mg/ml group was 92.4%, an 8.8% improvement compared to the placebo group (83.6%). The mean blood oxygen saturation for the untreated and unstimulated control group was 95.2%.
- Treatment with VYN201 1 mg/ml resulted in a 51.8% mean improvement in functional lung volume compared to animals receiving placebo treatment.
- Price Action: VYNE shares are up 48.2% at $4.64 on the last check Wednesday.
Cloudflare Collaborates With Meta, Microsoft And Nvidia: What’s Going On?
Cloudflare Inc (NYSE: NET) shares are trading higher Wednesday after the company announced collaborations with Meta Platforms Inc (NASDAQ: META), Microsoft Corp (NASDAQ:
